Nourin® protein is a potent inflammatory mediator rapidly released within 5 minutes by acute ischemic myocardium prior to necrosis. Nourin® protein is regulated by the hypoxia-induced miR-137 (a marker of cell damage) and the inflammation-induced miR-106b (a marker of inflammation). Nourin®-dependent microRNA-137 and miRNA-106b are novel myocardial ischemia/inflammation-dependent biomarkers with high diagnostic sensitivity and specificity for ACS.

The patented Nourin®-dependent miRNAs are novel diagnostic molecular biomarkers for myocardial ischemia and/or injury. Nourin miRNAs can identify acute myocardial ischemia prior to necrosis in patients suspected of having acute coronary syndrome (ACS), consisting of AMI and UA. In contrast with current biomarkers such as troponin, Nourin® miRNAs can reveal ischemia of the myocardium and confirm its resolution via coronary angioplasty.In contrast with current biomarkers such as troponin, Nourin® miRNAs can reveal ischemia of the myocardium and confirm its resolution via coronary angioplasty. The Nourin miRNA test will have a particular benefit for women since they frequently present with vague symptoms of “questionable angina” and their diagnose of myocardial ischemia, is difficult.

In summary, assessment of Nourin® miRNAs enables the rapid identification of a population of patients with ischemia, but without injury or infarction, thus potentially improving the treatment algorithms.

Nourexal® is a novel bioenergetic/anti-inflammatory drug that resuscitates poorly functioning hearts and protects against development of heart failure.

The FDA-designated bioenergetic/anti-inflammatory drug, Nourexal® (cyclocreatine phosphate - CCrP) is a cardiac therapeutic drug to prevent ischemia-induced injury and block the harmful downstream events of ischemia that lead to cardiac dysfunction and development of heart failure. Nourexal® resuscitates poorly functioning hearts and protects against development of heart failure post ischemia. Nourexal® is a New Paradigm that restores cellular energy (adenosine triphosphate (ATP)) despite hypoxia/ischemia. As a bioenergetic drug, CCrP protects hearts against ischemic injury and restores cardiac function during reperfusion. Clinical applications include, end-stage heart failure patients scheduled for heart transplantation procedure, patients undergoing high-risk cardiac surgery and high-risk intervention cardiology.

Professional Expertise:

A. Overall Summary:

• Dr. Elgebaly’s unique experience in academia, clinical trials in investigative sites, and pharmaceutical industry includes: 1) academic drug discovery and development at the University of Connecticut School of Medicine, 2) established two new Clinical Trials and Research Centers in Connecticut (Grove Hill Medical Center and Connecticut Multispecialty Group) and functioned as the Director of the Centers to oversee all FDA-regulated Phase II and Phase III clinical trials in local and international investigative sites, 3) established one new Clinical Trials and Research Center at University of Alexandria Faculty of Medicine, Alexandria, Egypt, and 4) functioned as the Director of Clinical Affairs in a Maryland-based pharmaceutical Company, AnGes Inc. which included FDA filing for drug registration for human use.
• Wrote a Review Article: Elgebaly SA, et al.: Cyclocreatine Protects Against Ischemic Injury and Enhances Cardiac Recovery During Early Reperfusion. Expert Review of Cardiovascular Therapy, Volume 17(9), 683-697, 2019.
• Presented recently seven abstracts related to Nourin® and Nourexal® at the American College of Cardiology (ACC), American Heart Association (AHA), and European Society of Cardiology (ESC). The abstracts are published at the Journal of American College of Cardiology (Impact Factor: 24), Circulation Journal (Impact Factor: 29), and European Heart Journal (Impact Factor: 39).
• Dr. Elgebaly is also a frequent lecturer in international conferences on the subject of Nourin® and Nourexal®, and Cyclosporin H. Specifically, Dr. Elgebaly was invited to present her work by:
  • Nobel Prize Winner in Medicine, Professor Sir John Vane, London, UK,
  • Nobel Prize Winner in Medicine, Professor R. Levi Montalcini, Rome, Italy,
  • Professor Sir Magdy Yacoub in London, United Kingdom.

B. Academic & Industrial Experience:

• Research & Development for heart-related diagnostic and therapeutic products.
• Dr. Elgebaly’s research resulted in the discovery of the potent tissue-derived inflammatory mediator, Nourin® and its antagonists Nourexin (Cyclosporin H (anti-inflammatory) and the cardioprotective, Nourexal® (Cyclocreatine Phosphate) (bioenergetic and anti-inflammatory / anti-apoptotic). Cyclosporine H (Nourexin) is also a potent anti-inflammatory drug against influenza flu-induced acute and chronic inflammation.
• Clinical trials in pharmaceutical setup and investigative sites (patients site).
• FDA requirements for product submission for approval.
• Participant, FDA-Sponsored Cardiac Safety Research Consortium
• Dr. Elgebaly has been awarded millions of dollars to support her research from such organizations as the National Institute of Health (NIH), academic institution such the University of Connecticut School of Medicine, as well as the Maryland Technology Development Cooperation, several pharmaceutical companies, corporate competitive awards and private funding.

C. Product Commercialization:

• Nourexal® (Cyclocreatine Phosphate) and FDA Orphan Drug Designation

Nour Heart was granted the Orphan Drug Designation (ODD) by U.S. Food and Drug Administration for its new patented drug Cyclocreatine Phosphate for the unique designation of: prevention of ischemic injury to enhance cardiac graft recovery and survival in heart transplantation (DRU-2015-4951).

• Cardiac Nourin Blood Test

Nourin® miRNAs will be developed as novel blood-based biomarkers to rapidly identify patients with myocardial ischemia seen at both outpatient clinics and emergency department. Nourin® miRNAs can potentially identify ACS patients at presentation.

D. Clinical Research and Clinical Trial Expertise:

Dr. Elgebaly has extensive experience in conducting FDA-regulated drug tested Phase II and Phase III clinical trials (also see details in attachment A below), pharmaceutical industry (Director of Clinical Affairs), as well as FDA filing for drug registration for human use. Dr. Elgebaly previously held the position of Director of Clinical Affairs in the pharmaceutical company, AnGes Inc. in Maryland, and she established in Connecticut and functioned as the Director of the two new Clinical Trials and Research Centers at the Investigative Sites; Grove Hill Medical Center and Connecticut Multispecialty Group. She successfully managed over 26 clinical studies and worked closely with over 80 physicians and surgeons. Furthermore, because of Dr. Elgebaly’s Nourin technology as a novel early biomarker for cardiac patients, she is an active participant with the FDA-sponsored Cardiac Safety Research Consortium-CSRC. Currently, Dr. Elgebaly functions as a Volunteer Official Consultant/Expert for the Egyptian Parliament for their efforts to establish the new Clinical Trials Law and the new Law to Govern Animal Facilities and Animal Use in Research.

Education:

1979

1975

1973

Postgraduate Training:

2006

1998

1979-1981

Appointments:

2006 - Present

2019 – 2021

2007 - 2012

2003-2006

2002 – 2003

2000 – 2002

1998-2000

1992-1997

1985-1992

1987-1988

1980-1985

1979-1980

Teaching Activities:

1986 – 1992

Management & Research Funding:

Dr. Elgebaly managed her own laboratory as a Principal Investigator at the University of Connecticut School of Medicine. During that period, Dr. Elgebaly, supervised over 40 employees, including surgical residents, cardiology fellows, postdoctoral fellows, medical and graduate students, college and high school students, and a number of technicians.

Dr. Elgebaly responsibilities involved supervising the overall directions of various projects, writing grants and scientific articles, presenting scientific results in various conferences, and managing various funds. As a Director of Clinical Trials & Research at Grove Hill Medical Center and Connecticut Multispecialty, Dr. Elgebaly established the two Clinical Trials & Research departments and successfully managed over 26 clinical studies and worked closely with over 80 physicians and surgeons.

Dr. Elgebaly has been awarded millions of dollars to support her research from such organizations as the National Institute of Health (NIH), academic institution such the University of Connecticut School of Medicine, as well as the Maryland Technology Development Cooperation, several pharmaceutical companies, corporate competitive awards and private funding. For the past 7 years, Nour Heart funded all R&D work.

Honors and Awards:

2024

2022

2019

2007-2010

1998

1985

1979-1980

1976-1979

1973-1975

1973

Memberships

2023-present

1992-present

2012-present

2021-present

2019-present

2007-2010

Professional Accomplishments

2021-present

2005 – Present

2006 - Present

2012 – 2016

2010 – 2012

2004 – 2007

2003

2000

2000 – 2002

2000 – 2001

Patents Issued from U.S. Patent Office, Washington DC:

1. Elgebaly SA: Nourin Gene-Based RNA Molecular Network: Novel Early Diagnostic and Prognostic Biomarkers for Coronary Artery Disease, Unstable Angina, STEMI/NSTEMI and Heart Failure (US Patent #16,948240).

2. Cyclocreatine Phosphate: A Novel Bioenergetic Therapy to Prevent and Treat Ischemia-Induced Aging Related Cardiovascular and Neurodegenerative diseases. (US Patent # 16-948-235).

3. Elgebaly SA: Nourin Molecular Biomarkers Diagnose Angina Patients with Negative Troponin (# 16719723).

4. Elgebaly Salwa Ahmed and Marwa Matboli Sayed: A Novel Autophagy-Related Nourin Gene- Based RNA Network as Early Biomarkers for Cardiac Patients (# 10895572).

5. Elgebaly SA, Elliott Schiffmann & Tamer Elbayoumi: Nourexin-4 Nano-Lipid Emulsions (US #8,333,987).

6. Elgebaly SA and Elliott Schiffmann: Methods to Prevent & Treat Diseases (# 8,288,350).

7. Farghaly A and Elgebaly SA: Phosphagen Synthesis (# 7,964,736).

8. Elgebaly SA and Elliott Schiffmann: Mitochondrial Marker of Ischemia – (#7,662,571).

9. Elgebaly SA: Diagnostic Marker (#7,659,091).

10. Elgebaly SA: Antibodies to a Neutrophil Chemotactic Protein (#5,606,027).

11. Elgebaly SA: Diagnostic Test Procedure for Urinary Tract Inflammatory Condition (US #5,318,891).

12. Elgebaly SA: Methods for Restoring Functionality in Muscle Tissue (#5,091,404).

13. Elgebaly SA: Biological Mediators of Immune Function (#5,403,914).

Trademark Accepted and Pending Application from USPTO, Washington DC:

NOURIN® Registration
NOTICE OF ACCEPTANCE OF STATEMENT OF USE U.S. Serial Number: 88-768,088 Mark: NOURIN Owner: Nour Heart, Inc.

NOUREXAL® Registration
NOUREXAL® (Cyclocreatine Phosphate) Registered Trademark from USPTO: U.S. Serial Number: 88854341

Selected Publications:

PEER REVIEWED AND INVITED ARTICLES

Dr. Elgebaly’s publications appeared in prestigious journals such as:

• Science
• J Thorac and Cardiovascular Surgery
• Ann Thorac Surg
• J Transplantation
• J Urology
• J Pathology
• J Molecular and Cellular Cardiology
• J Pharmacology Experimental Therapy
• J Pharmaceutical Science
• J Expert Review of Cardiovascular Therapy
• J National Cancer Institute
• Current Eye Research
• Oncology
• Biomolecules
• Diagnostics
• Int. J. of Molecular Science.

1. Salwa A. Elgebaly, Charles Van Buren, Robert Todd, Robert Poston, Reem K. Arafa, Nashwa El-Khazragy, Donald Kreutzer, Mostafa A. Rabie, Ahmed F. Mohamed, Lamiaa A. Ahmed, and Nesrine S. El Sayed. Cyclocreatine Phosphate: A Novel Bioenergetic/Anti-inflammatory Drug that Resuscitates Poorly Functioning Hearts and Protects Against Development of Heart Failure. Invited Paper to the Special Issue “Adenosine Metabolism-Key Targets in Cardiovascular Pharmacology”, Pharmaceuticals 2023, 16(3), 453.
2. Salwa A. Elgebaly, W. Frank Peacock, Robert H. Christenson, Donald L. Kreutzer, Ahmed Hassan Ibrahim Faraag, Amir Mahfouz Mokhtar Sarguos, and Nashwa El-Khazragy. Integrated Bioinformatics Analysis Confirms the Diagnostic Value of Nourin-Dependent miR-137 and miR-106b in Unstable Angina Patients. Invited Paper to the Special Issue “New Insights into Cardiovascular Diseases in Basic Research”, Int. J. Mol. Sci. 2023, 24(19).
3. Salwa A. Elgebaly, Robert H. Christenson, Hossam Kandil, Nashwa El-Khazragy, Laila Rashed, Beshoy Yacoub, Heba Eldeeb, Mahmoud Ali, Roshanak Sharafieh, Ulrike Klueh and Donald L. Kreutzer. Nourin-Dependent miR-137 and miR-106b: Novel Early Inflammatory Diagnostic Biomarkers for Unstable Angina Patients. Invited Paper to the Special Issue “Molecular Biomarkers in Cardiology,” Biomolecules 2021, 11(3), 368.
4. Salwa A. Elgebaly, Robert H. Christenson, Hossam Kandil, Mohsen Ibrahim, Hussien Rizk, Nashwa El-Khazragy, Laila Rashed, Beshoy Yacoub, Heba Eldeeb, Mahmoud Ali, and Donald L. Kreutzer. Nourin-Dependent miR-137 and miR-106b: Novel Biomarkers for Early Diagnosis of Myocardial Ischemia in Coronary Artery Disease Patients. Diagnostics 2021, 11(4), 703.
5. Salwa A. Elgebaly, Robert Todd, Donald L. Kreutzer, Robert H. Christenson, Nashwa El-Khazragy, Reem K. Arafa, Mostafa A. Rabie, Ahmed F. Mohamed, Lamiaa A. Ahmed, and Nesrine S. El Sayed. Nourin-Associated miRNAs: Novel Inflammatory Monitoring Markers for Cyclocreatine Phosphate Therapy in Heart Failure. Invited Paper to the Special Issue “Positive and Negative Determinants of Ischaemic Injury-Co-morbidities and Cardioprotection 2020,” Int. J. Mol. Sci. 2021, 22(7), 3575.
6. Ibrahim F. Abo-Elmagd, Amr M. Mahmoud, Medhat A. Al-Ghobashy, Marianne Nebsen, Nesrine S. El Sayed, Shahira Nofal, Sameh H. Soror, Tobert Todd, Salwa A. Elgebaly. Impedimetric Sensors for Cyclocreatine Phosphate Determination in Plasma Based on Electropolymerized Poly(o-phenylenediamine) Molecularly Imprinted Polymer. ACS Omega. 2021, Nov 23; 6(46): 31282–31291.
7. Salwa A. Elgebaly, Robert Poston, Robert Todd, Tarek Helmy, Abdallah M Almaghraby, Tamer Elbayoumi, and Donald L Kreutzer. Cyclocreatine Protects Against Ischemic Injury and Enhances Cardiac Recovery During Early Reperfusion.Expert Review of Cardiovascular Therapy,Expert Review of Cardiovascular Therapy,Volume 17, 2019 Issue 9 (

   REVIEW

   ).
8. Elgebaly SA, Elbayoumi T and Kreutzer DL. Cyclosporin H: A Novel Anti-inflammatory Therapy for Influenza Flu Patients. Journal of the Egypt. Soc. of Parasitol.: Apr;47(1):25-33, 2017.
9. Christenson R, Elgebaly SA: Nourin-1: The "Holy Grail" for Assessing Myocardial Ischemia. ADVANCE 16 (1), 19-21, 2004.
10. Houser SL, El-Kerm AF, Wei A, Doyle K, Houser D, Tyles E, Kaddurah-Daouk R and Elgebaly SA: Enhancement of cardiac function by cyclocreatine in models of cardiopulmonary bypass. J Mol Cell Cardiol. Volume 27, Issue 4, April, Pages 1065-1073, 1995.
11. Elgebaly SA, Houser SL, El-Kerm AF, Doyle K, Gillies C and Dalecki K: Evidence of cardiac inflammation after open heart surgery. Ann Thorac Surg. 1994 Feb;57(2):391-6.
12. Elgebaly SA, Wei Z, Tyles E, El-Kerm AF, Houser SL, Gillies C and Kaddurah-Daouk R: Enhancement of the recovery of rat hearts after prolonged cold storage by cyclocreatine phosphate. J. Transplantation. 1994 Mar 27;57(6):803-6.
13. Elgebaly SA, Miano D, Ehler W, Rahhal F and El-Kerm A: The induction of anterior chamber inflammation by factors releaseed from hydrogen peroxide-injured corneas: effect of dexamethasone and indomethacin. Ocular Pharmacol. Spring; 10(1):295-306, 1994.
14. Shames NBK, Reddy DV, Watanabe K, Elgebaly SA, Hanninen LA and Kenyon KR: Increased Interleukin-1 activity in the injured Vitamin A-deficient cornea. Cornea. 13(2):156-166, 1994.
15. Elgebaly SA, Hashmi F, Houser S, Allam ME, Doyle K. Cardiac-derived neutrophil chemotactic factors: detection in coronary sinus effluents of patients undergoing myocardial revascularization. J Thorac Cardiovasc Surg. 103(5): 952–959, 1992.
16. Elgebaly SA, Allam ME, Houser S, Hashmi F, Forouhar F and Miano D: Cyclocretaine inhibits neutrophil accumulation in the myocardium of a canine model of coronary artery occlusion and reperfusion. J Pharmacol Exp Therap. 266(3):1670-1677, 1993.
17. Elgebaly SA, Gillies C, Shimizu RW, Anger CB, Spencer JA, Buchen SY: Effects of visoelastic solutions on neutrophil function and the release of neutrophil chemotactic factors from isolated bovine corneas. Cornea. 3(2):28-34, 1993.
18. Elgebaly SA, Allam ME, Walzak MP and Oselinksy D: Urinary neutrophil chemotactic factors in interstitial cystitis patients and a rabbit model of bladder inflammation. J Urol. 147:206-211, 1991.
19. Elgebaly SA, Donshik P, Rahhal F and Williams W: The detection of neutrophil chemotactic factors in tears of giant papillary conjunctivitis patients: role of conjunctival tissue. Invest Ophthalmol Vis Sci. 32:208-213, 1991.
20. Ehlers W, Williams W and Elgebaly SA: Conjunctiva-derived neutrophil chemotactic factors: preliminary biochemical characterization. CLAO J. 17:65-68, 1991.
21. Elgebaly SA, Allam ME, Rossomando EF, Forouhar F, Farghaly A and Kreutzer DL: Cyclocreatine inhibits the production of neutrophil chemotactic factors from isolated hearts. Am J Pathol. 137: 1233-1241, 1990.
22. Kozol RA, Punzo A, Ribaudo R, Rossomando EF and Elgebaly SA: Neutrophil chemotactic activity in gastric secretions. Arch Surg. 125(4):454-456, 1990.
23. Ruby ST, Allam M, Gallo M, Barth S and Elgebaly SA: Release of chemotactic factors by veins during preparation for arterial bypass. Arch Surg. 125(4):481-485, 1990.
24. Riley M and Elgebaly SA: Release of a neutrophil chemotactic factor from UV-irradiated rabbit corneas. Curr Eye Res. 9(7):677-682, 1990.
25. Elgebaly SA, Miano D, Fishman J and Kreutzer DL: Cornea-derived neutrophil chemotactic factors: intracellular synthesis and release. Curr Eye Res. 9(9):839-845, 1990.
26. Elgebaly SA, Masetti P, Allam M and Forouhar F: Cardiac-derived neutrophil chemotactic factors: preliminary biochemical characterization. J Mol Cell Cardiol. 21:585-593, 1989.
27. Kozol RA, Downes RA, Kreutzer DL, Wentzel S, Rossomando FF and Elgebaly SA: Release of neutrophil chemotactic factors from gastric tissue: initial biochemical characterization. Dig Dis Sci. 34:68-687, 1989.
28. Elgebaly SA, Herkert N, O’Rourke J and Kreutzer DL: Characterization of neutrophil and monocyte-specific chemotactic factors derived from isolated corneas in response to immunologic injury. Am J Pathol. 126:22-32, 1987.
29. Kozol RA, Gillies C, Elgebaly SA: Effects of Sodium Hypochlorite (Dakin's Solution) on Cells of the Wound Module. Arch Surg. 123(4):420-423, 1988.
30. Elgebaly SA, Downes R, O’Rourke J and Kreutzer DL: Characterization of inflammatory mediators such as leukocyte chemotactic factors produced by isolated corneas in response to alkali injury. Curr Eye Res. 6:1263-1274, 1987.
31. Elgebaly SA, Barton R and Forouhar F: Reversal of radiation-induced leukemogenesis in mice by immunomodulation with thiabendazole and dinitrofluourbenzene. J Natl Cancer Inst. 74(4):811-815, 1985.
32. Elgebaly SA, Gillies C, Forouhar F, Hashem M, Baddour M, O’Rourke J and Kreutzer DL: An in vitro model of leukocyte-mediated injury to the corneal epithelium. Curr Eye Res. 4(1):31-41, 1985.
33. Elgebaly SA, Herkert N, Gillies CC, Picciano PT, Donaldson MC, Kreutzer DL. Influence of anti-endothelial cell antibodies on the interactions of leukocytes with vascular endothelial cells in vitro. J Exp Pathol. Spring 2(1):59-73, 1985.
34. Elgebaly SA, Forouhar F and Dore-Duffy P: Thiabendazole-induced suppression of renal damage in a murine model of autoimmune disease. Am J Pathol. 115:204-211, 1984.
35. Elgebaly SA, Forouhar F, Gillies C, O’Rourke J and Kreutzer DL: Leukocyte-mediated injury to corneal endothelial cells: a model of tissue injury. Am J Pathol. 116(3):407-416, 1984.
36. Elgebaly SA, Varani J, Kunkel SL and Ward PA: Cyclic AMP levels in subpopulations of tumor cells: correlation with in vitro and in vivo behavior. Oncology. 39:163-166, 1982.
37. Varani J, Lovett EJ III, Elgebaly SA and Lundy J: In vitro and in vivo adherence of tumor variants correlated with malignant potential. Am J Pathol. 111:345-353, 1980.
38. Elgebaly SA, Hall IH, Lee KH, Sumida Y, Imakura Y and Wu RY: Antitumor agent XXVI: effect of brutasol, bruceoside A and bruceantin on P-388 lymphocytic leukemia cell respiration. J Pharm Sci. 68(7):888-890, 1979.
39. Lee KH, Hall IH, Mar EC, Starnes CO, Elgebaly SA, Waddel TG, Hadgraft RI, Ruffner EG and Weidner I: Sesquiterpene anti-tumor agents: inhibitors of cellular metabolism. Science. 196:533-536, 1977.

Book Chapters

1. Salwa A. Elgebaly, et al. Nourin-Dependent miR-137 and miR-106b: Novel Early Inflammatory Diagnostic Biomarkers for Unstable Angina Patients. Textbook chapter “Molecular Biomarkers in Cardiology,” Biomolecules 2021, 11(3), 368.
2. Elgebaly SA, Kozol RA and Kreutzer DL: Alcohol and immune system: role of gastric tissue. In: Alcohol Immunomodulation and AIDS Proceedings (Pawlowski A, Seminara D, Watson R, eds). Symposium on indirect mechanisms of immune modulation. Textbook chapter AR Liss, Inc.: New York, Vol.325, 1989.pp 75-78.
3. Kozol RA and Elgebaly SA: Ethanol and its effect on mucosal immunity. In: Drugs of Abuse and Immune Function (Watson R, ed). Textbook chapter CRC Press: Colorado, 1989.pp 165-173.

Manuscripts in Preparation for 2024 Submission

1. Salwa A. Elgebaly, W. Frank Peacock, IV, Michael A. Azrin, Emerson C. Perin, Nashwa El-Khazragy, Robert Fuller, Don Kreutzer, Robert H. Christenson. microRNA-137 and miRNA-106b are novel myocardial ischemia/inflammation-dependent biomarkers with high diagnostic sensitivity and specificity for acute coronary syndrome (ACS). Abstract published in the American College of Cardiology, Accepted as Oral Presentation, J. Am. Coll. Cardiol., 2024.

2. Kandil H, Yacoub B., Sadaka M, Yehia A, El-Khazragy N, Rashed L, El-Hadidi AS, Kreutzer DL, Christenson RH, and Elgebaly SA. Nourin miRNAs: novel biomarkers highly expressed in unstable angina patients with normal ECG and negative hs-troponin and dropped post percutaneous coronary intervention. Abstract published in the European Heart Journal, vol. 44, Volume 44, Issue Supplement_2, November 2023.

ORAL PRESENTATIONS - PEER-REVIEWED SUBMISSIONS

Scientific Conferences Include:

• American College of Cardiology (J Am. Coll. Cardiol.)
• European Society of Cardiology (European Heart Journal)
• American Heart Association (Circulation J)
• American Association of Immunologists (J. Immunology)
• American College of Surgeons (Surgical Forum)
• Society for Cardiovascular Angiography & Intervenions (Catheterization & Cardiovascular Interventions)
• American Society of Transplant Surgeons
• Association for Research in Vision and Ophthalmology (Invest Ophthalmology Visual Science)
• International Society for Heart Research (J Mol Cell Cardiol.)
• World Congress of the International College of Surgeons
• European Cardiology Conference (J Clin. Exp. Cardiology)
• Global Summit on Heart Diseases and Therapeutics (J Clin. Exp. Cardiology).

1. Salwa A. Elgebaly, W. Frank Peacock, IV, Michael A. Azrin, Emerson C. Perin, Nashwa El-Khazragy, Robert Fuller, Don Kreutzer, Robert H. Christenson. MmicroRNA-137 and miRNA-106b are novel myocardial ischemia/inflammation-dependent biomarkers with high diagnostic sensitivity and specificity for acute coronary syndrome (ACS). Highlighted Original Research: Ischemic Heart Disease and the Year in Review - Oral Contributions, 2024 American College of Cardiology (ACC) Conference, J. Am. Coll. Cardiol., 83,(13) 1151, 2024.
2. Kandil H, Yacoub B., Sadaka M, Yehia A, El-Khazragy N, Rashed L, El-Hadidi AS, Kreutzer DL, Christenson RH, and Elgebaly SA. Nourin miRNAs: novel biomarkers highly expressed in unstable angina patients with normal ECG and negative hs-troponin and dropped post percutaneous coronary intervention. European Heart Journal, vol. 44, Volume 44, Issue Supplement_2, November 2023.
3. Elgebaly, S.A.; Poston, R.; van Buren, C.; Todd, R.; Arafa, R.; El-Khazragy, N.; Rabie, M.; Mohamed, A.; Ahmed, L.; Sayed, N.E.: A Novel High Energy Phosphate Source Resuscitates Poorly Functioning Donor Hearts. Circulation J. 146, A9706, (abstract) 2022.
4. Elgebaly, S.A.; Christenson RH, Azrin M, Rizk H, El-Khazragy N, Kreutzer DL, Van Buren C, and Poston R.: Nourin Mirnas: Novel Blood Biomarkers for Early Identification or Exclusion of Myocardial Ischemia in Women Suspected of Having Coronary Artery Disease (CAD). Circulation J. 146:A9773) (Abstract) 2022.
5. Elgebaly, S.A.; Christenson, R.H.; Kandil, H.; El-Khazragy, N.; Rashed, L.; Yacoub, B.; Sharafieh, R.;  Klueh, U.; Kreutzer, D.L.: Nourin-dependent Mirna-137: A Novel Early Diagnostic Biomarker for Unstable Angina Patients. Circulation J. Virtual Meeting – 17 Nov. 142:A13051, 2020.
6. Elgebaly, S.A.; Christenson, R.H.; Kandil, H.; ElKhazragy, N.; Rashed, L.; Yacoub, B.; Sharafieh, R.;Klueh, U.; Kreutzer, D.L. Abstract 13103: Nourin-dependent Mirna-106b: A Novel Early Inflammatory Diagnostic Biomarker for Cardiac Injury. Circulation J. Virtual Meeting – 17 Nov. 142:A13103, 2020.
7. Elgebaly, S.A.; Van Buren, C.; Todd, R.; Poston, R.; Rabie, M.A.; Mohamed, A.F.; Ahmed, L.A.; El Sayed, N.S. Cyclocreatine Phosphate: A Novel Mechanism for Preventing Development of Heart Failure. Circulation J. Virtual Meeting – 17 Nov. 142:A13311, 2020.
8. Elgebaly, S.A.; Nourexal: A Novel Anti-inflammatory / Antiapoptotic Therapy Against Reperfusion Injury. Heart Diseases and Therapeutics. J Clin. Exp. Cardiology. Chicago, IL. October Vol. 7(9),33, 2016.
9. Elgebaly, S.A.; Nourexal (Cyclocreatine Phosphate): A New Cardioprotective Therapy Against Reperfusion Injury. Heart Diseases and Therapeutics. J Clin. Exp. Cardiology. Madrid, Spain. December Vol. 7(11),19-20, 2016.
10. Elgebaly, S.A.; Elliott Schiffmann, Ahmed Farghaly, Tamer Elbayoumi, Donald Kreutzer, Cyclocreatine Phosphate is an Effective Cardioprotective Agent against Ischemic Injury. Catheterization & Cardiovascular Interventions. Los Vegas, Nevada. May 84:S1-S2, 2014.
11. Elgebaly, S.A.; Christenson R, Schiffmann E, Qiao Yi. and Kreutzer DL. Early Identification of Cardiac Ischemia Patients in the Emergency Department. Catheterization & Cardiovascular Interventions. Orlando, Florida. May 81:S2-S3, 2013.
12. Elgebaly, S.A.; Daniel Perez, Kathleen Sullivan, Craig Whitaker, Stephanie Caspe, Qiao Yi, and Donald L. Kreutzer. Nourexin-4: A Novel Anti-inflammatory Therapy for Influenza Flu. of Immunology. Baltimore, Maryland. April 184 (1 Supplement) 52.1, 2010.
13. Elgebaly, S.A.; and Kreutzer DL: Release of a potent inflammatory mediator from ischemic brain. 27^th International Stroke Conference. American Heart Association, San Antonio, Texas, February 2002.
14. Elgebaly, S.A.; House SL, Tyles E, El-Kerm AF, Mauri F and Kreutzer DL: Characterization of a novel small molecular weight neutrophil chemotactic factor human hearts.  Circulation J. San Francisco, CA. 86(4), 1996.
15. Tyles E, Houser SL, Shams NK, Consoli KA and Elgebaly SA: Nourin-1 stimulates the secretion of cytokines by neutrophils:  Inhibition by Anti-Nourin-1 Antibody. Circulation J. Chicago, IL. November 92(8), 1995.
16. Tyles E, Houser SL, Shams N, Consoli K and Elgebaly SA: Coronary sinus effluents from cardiopulmonary bypass patients stimulate the secretion of cytokines and adhesion molecules by vascular endothelial cells.  Circulation J. Miami Beach, FL. November 90(4), 1994.
17. Elgebaly, S.A.; Tyles E and Kulkarni P: Endotoxin-stimulated release of Nourin-1:  A novel 3 kDa cornea-derived chemotactic factor for neutrophils and monocytes.  Invest Ophthalmology Visual Science. Sarasota, FL. May 1994.
18. Tyles E, Kulkarni P and Elgebaly SA: Release of neutrophil chemotactic factors from ischemic-injured retinal tissue independent of dexamethasone treatment.  Invest Ophthalmology Visual Science. Sarasota, FL. May 1994.
19. Elgebaly, S.A.; Wei J, El-Kerm AF, Tyles E and Gillies C: Cyclocreatine phosphate significantly improves rat heart function after long-term hypothermic storage.  American Society of Transplant Surgeons. Houston, TX. May 1993.
20. Elgebaly, S.A.; Tyles E, Houser SL, El-Kerm AF and Mauri F: Partial purification of a novel cardiac-derived neutrophil chemotactic factor:  Nourin-1. Circulation J. New Orleans, Louisiana. November 88(4), 1993.
21. Elgebaly, S.A.; Houser S, El-Kerm AF, Doyel K and Perlman K: Evidence of cardiac inflammation after open heart surgery.  Surg Forum. Chicago, IL. 41:274-278, 1991.
22. Allam ME, Houser S, Hashmi F, Liu X, Cordis G and Elgebaly SA: Myocardial preservation by cyclocreatine: restoration of post-ischemic myocardial contractility. Surg Forum. San Francisco, CA. 246-249, 1990.
23. Elgebaly, S.A.; Cohen A, Allam M, Yekta N. Cardiac Derived Inflammatory Mediators. J Mol Cell Cardiol. Ann Arbor, Michigan. May 21(11),S 171, 1989.
24. Elgebaly, S.A.; Masetti P, Forouhar F, Rossomando EF, Cohen A. Ibuprofen fails to inhibit the release of the tissue-derived neutrophil chemotactic factors “Nourin” from ischemic hearts.  XXVI World congress of the International College of Surgeons.  July 3-9, Milan, Italy, 1988.
25. Elgebaly, S.A.; Kozol RA, Masetti P, Bohr M and Lennan C: Release of neutrophil chemotactic factors from ischemic myocardial tissues. Surg Forum. San Francisco, CA. 38:276-279, 1988.
26. Elgebaly, S.A.; Masetti P and Bohr M: The release of neutrophil chemotactic activity from ischemic coronary artery.  Eleventh International Reticuloendothelial Society Meeting. Kawai, Hawaii, 1987.
27. Elgebaly, S.A.; O’Rourke J and Kreutzer DL: Characterization of leukocyte chemotactic factors released by isolated corneas in response to injury (chemical vs. mechanical).  In Vitro Toxicology Symposium, Johns Hopkins University, Center for Alternatives to Animal Testing, Baltimore, MD, 1986 (invited abstract).
28. Elgebaly, S.A.; Donovan M, Forouhar F, Gillies C, O’Rourke J and Kreutzer DL: Morphologic study of leukocyte-mediated injury to corneal endothelium.  Invest Ophthalmology Visual Science. Sarasota, FL, May 1983.

INVITED PRESENTATIONS

• At professional conferences
• At another college or university or scholarly institution.

1. Elgebaly SA, Cyclosporine H:  A Novel Anti-Inflammatory Therapy with Applications for COVID-19 Patients. Reshaping Pharma Sustainability and Innovation for Better Pandemic Response. University of Cairo, Faculty of Pharmacy, Cairo, Egypt, July, 2021 (Virtual).
2. Elgebaly SA, Cyclocreatine Phosphate: A Novel Mechanism for Preventing Development of Heart Failure. Global Virtual Summit on Cardiology and Cardiovascular Medicine. July, 2021. (Virtual).
3. Elgebaly SA, Cyclocreatine phosphate: A novel mechanism for preventing development of heart failure. 20^th CardioAlex Scientific Conference, University of Alexandria, Alexandria, Egypt, June, 2021. (Virtual).
4. Elgebaly SA. Nourin molecular biomarkers detect early myocardial ischemia. CardioAlex Conference, Alexandria, Egypt, June, 2020. (Virtual).
5. Elgebaly SA. Innovative Medicines in Africa: Our Own Experience with Cyclocreatine as a Novel FDA-Designated Cardioprotective Drug. 1^st International Conference on African Studies Sustainable development for Africa, Cairo, Egypt, December, 2019.
6. Elgebaly SA. Innovative Medicines in Egypt: Our Own Experience with Cyclocreatine as a Novel FDA-Designated Cardioprotective Drug. International Conference on Pharmaceutical and HealthCare Sciences, Alexandria, Egypt, November, 2019.
7. Elgebaly SA. Innovative Medicines in Egypt: Our Own Experience with Cyclocreatine as a Novel FDA-Designated Cardioprotective Drug. Saina University, Faculty of Pharmacy, Saina, Egypt, November, 2019.
8. Elgebaly SA. Innovative Medicines in Egypt: Our Own Experience with Cyclocreatine as a Novel FDA-Designated Cardioprotective Drug. University of Cairo, Faculty of Pharmacy, Cairo, Egypt, October 2019.
9. Elgebaly SA. Innovative Medicines in Egypt: Our Own Experience with Cyclocreatine as a Novel FDA-Designated Cardioprotective Drug. Zewail City of Science and Technology (Laureate Ahmed Zewail), Cairo, Egypt, October 2019.
10. Elgebaly SA. A novel autophagy related Nourin gene-based RNA network as early biomarkers for cardiac patients. CardioAlex Conference, Alexandria, Egypt, June 2019.
11. Elgebaly SA. Nourin: A Novel Cardiac Biomarker. Egyptian Society of Cardiology, Cairo, Egypt, February, 2019.
12. Elgebaly SA. Drug Manufacturing in Egypt: Opportunities, Challenges and Strategies for Success - Workshop #4, University of Ain Shams, Faculty of Pharmacy, Cairo, Egypt, December, 2018.
13. Elgebaly SA. Keynote Speaker: Translational Science from Bench to Patients: Our Own Experience with Cyclocreatine as a Novel FDA-Designated Drug. Association of Egyptian American Scholars (AEAS), Cairo, Egypt, December, 2018.
14. Elgebaly SA. Keynote Speaker: Innovative Medicines in Egypt. Association of Egyptian American Scholars (AEAS), Cairo, Egypt, December, 2018.
15. Elgebaly SA. Drug Manufacturing in Egypt: Opportunities, Challenges and Strategies for Success - Workshop #4, University of Helwan, Faculty of Pharmacy, Cairo, Egypt, September, 2018.
16. Elgebaly SA. Clinical Trials and FDA Filing for Product Approval - Workshop #3, University of Helwan, Faculty of Pharmacy, Cairo, Egypt, May, 2018.
17. Elgebaly SA. Keynote Speaker: Drug Manufacturing in Egypt: Opportunities and Challenges. The Academy of Scientific Research and Technology (ASRT), “Promoting Egyptian Potentials”, Cairo, Egypt, March 2018.
18. Elgebaly SA. Cyclocreatine: A Novel Cardioprotective Therapy for Ischemic Heart Disease (IHD) Patients. University of Alexandria, Faculty of Pharmacy, Alexandria, Egypt, January, 2018.
19. Elgebaly SA. Keynote Speaker: Development and Commercialization of ‘Branded’ Medicines in Egypt. Association of Egyptian American Scholars (AEAS), Cairo, Egypt, December, 2017.
20. Elgebaly SA. Keynote Speaker: “From Drug Discovery to Commercialization: Sharing Best Practices from International Perspective”. The Academy of Scientific Research and Technology (ASRT), Arab-German Young Academy of Sciences and Humanities (AGYA). Mapping and Strengthening the Regenerative Medicine Landscape in Egypt. Sahl Hasheesh, Sharm Elsheikh, Egypt, October 2017.
21. Elgebaly SA. Intellectual Property (IP) of Nourexal™ and Product Funding - Workshop #2, University of Helwan, Faculty of Pharmacy, Cairo, Egypt, October, 2017.
22. Elgebaly SA. Nourexal™: A Novel Anti-inflammatory / Anti-apoptotic Therapy Against Reperfusion Injury. University of Cairo, Faculty of Pharmacy, Cairo, Egypt, November, 2016.
23. Elgebaly SA. Nourexal™: A Novel Anti-inflammatory / Anti-apoptotic Therapy Against Reperfusion Injury. University of Alexandria, Faculty of Medicine, Alexandria, Egypt, November, 2016.
24. Elgebaly SA. Entrepreneurship in Pharmaceutical Drug Development (Nourexal™) - Workshop #1, University of Helwan, Faculty of Pharmacy, Cairo, Egypt, April, 2016.
25. Elgebaly SA. Nourexin-4: A Novel anti-inflammatory therapy for cardiac inflammation and MRSA infection after cardiac catheterization and surgery. Egyptian Cardiology meeting, Sharm Elsheikh, Egypt, February, 2009.
26. Elgebaly SA. Myocardial protection by the anti-apoptotic drug Nourexal. Egyptian Society of Cardiology, Sharm Elsheikh, Egypt, February, 2009.
27. Elgebaly SA. Nourin Family: A Novel Therapeutic Target for the Development of Tissue-Specific Anti-Inflammatory Drugs. University of Alexandria Faculty of Pharmacy, Alexandria, Egypt – March, 2006.
28. Elgebaly SA. Conducting Clinical Research in Egypt: How & FDA Requirements. University of Alexandria Faculty of Medicine, Alexandria, Egypt – March, 2006.
29. Elgebaly SA. Responsibilities of Clinical Investigators. Cardio Alex 2006, Alexandria, Egypt – June 28, 2006.
30. Elgebaly SA. Recruiting and maintaining study patients. Cardio Alex 2006, Alexandria, Egypt – June 29, 2006.
31. Elgebaly SA. New therapeutic pharmacologic approaches for the treatment of diabetic retinopathy. Retinal Aspen Institute, Aspen Colorado, August 2005 (Invited Speaker by Dr. Bert Glaser).
32. Elgebaly SA, Kreutzer DL, Mauri F, Azrin M, Fuller R, Christenson R: Nourin-1: an early diagnostic marker for myocardial ischemia and infarction to distinguish cardiac patients from non-cardiac patients presenting in emergency room with chest pain. International Egyptian Society of Cardiology, Alexandria, Egypt, February, 2002.
33. Elgebaly SA. Hypertension and Stroke: Pathogenesis, Diagnosis & Treatment. 15^th Annual Conference of the Egyptian Society of Hypertension, Cairo, Egypt, January, 2001.
34. Elgebaly SA. Hypertension: Pathogenesis & Treatment, Lecture #I. 14^th Annual Conference of the Egyptian Society of Hypertension, Cairo, Egypt, January 2000.
35. Elgebaly SA. Hypertension: Pathogenesis & Treatment, Lecture #II. 14^th Annual Conference of the Egyptian Society of Hypertension, Cairo, Egypt, January 2000.
36. Elgebaly SA. The role of infections and inflammation in the pathogenesis of coronary heart disease. 26^th annual conference of the Egyptian Society of Cardiology, Cairo, Egypt, February 1999.
37. Elgebaly SA. Hypertension, Inflammation and coronary heart disease. 26^th annual conference of the Egyptian Society of Cardiology, Cairo, Egypt, February 1999.
38. Elgebaly SA. The cardiac-derived cytokine Nourin-1: Diagnostic and therapeutic applications.  International Symposium on Heart Disease, Cairo, Egypt, May 1998.
39. Elgebaly SA, Houser SL, El-Kerm A, Houser D, Kaddurah-Daouk R and Tyles E: Myocardial protection by cyclocreatine. Twenty-fourth Cardiac Surgery Meeting, London, England, May 1994.
40. Elgebaly SA Tyles E, Houser SL and El-Kerm AF: Cardiac-derived inflammatory mediators. Interscience World Conference on Inflammation, Antirheumatics, Analgesics, Immunomodulators, Geneva, Switzerland, April 1993.
41. Elgebaly SA. Cyclocreatine: A Potent Cardioprotective Drug. Invited by Professor Sir Magdy Yacoub, London, UK. July, 1994.
42. Elgebaly SA. Nourin: A Novel Tissue-Derived Inflammatory Mediator. Invited by the Nobel Prize Winner in Medicine, Professor Sir John Vane,

    London, UK,

    July, 1993.
43. Elgebaly SA. Nourin: A Novel Tissue-Derived Inflammatory Mediator. Invited by the Nobel Prize Winner in Medicine, Professor R. Levi Montalcini,

    Rome, Italy,

    July, 1993.

Attachment A

Clinical Trial & Research Expertise:

Expertise in National and International Biomedical Industrial Field, includes:

• Industrial Drug Development (R&D);
• Industrial Clinical Research and FDA submissions;
• FDA regulations & guidelines;
• Clinical Trials conducted in Investigative Sites; and
• International Clinical Trials including:
  • Europe (United Kingdom)
  • Europe (Holland)
  • Japan
  • China
  • Egypt

Industrial R&D & Clinical Research Experience:

• Director of Clinical Research in Nour Heart with the goal to develop diagnostic and therapeutic products for patients with ischemic heart disease.  
• Director of Clinical Affairs in the Pharmaceutical Company AnGes, Gaithersburg, MD.
•  Consultant Director of the Nourin project in the company Unipath, Bedford, UK, with focus on also     
• developing diagnostic and therapeutic products in the field of cardiovascular diseases. 

Clinical Research Activities Included:
• Designing and writing study protocols;
• Supervising preclinical efficacy studies in U.S., Europe and China;
• Evaluating study results;
• Filing IND to FDA;
• Responding to FDA questions;
• Selecting CROs and assuring timely completion of clinical studies within budget;
• Selecting Investigative Sites and conducting Investigators Meetings.

Clinical Trials Experience to Include Over 26 Clinical Studies (Phase II, Phase III, and Phase IV) in the field of Oncology, Cardiovascular, Infections, Psychiatry, Pulmonary, Rheumatoid Arthritis, Diabetes, Erectile Dysfunction, Surgery, Gene Analysis: